

News Release

November 12, 2010

Affectis Pharmaceuticals Appoints Manfred Rüdiger as Chief Executive Officer

Martinsried, Germany, November 12, 2010 – Affectis Pharmaceuticals AG announced today the appointment of Dr. Manfred Rüdiger as Chief Executive Officer and Vorstand. He succeeds Alex Martin who recently left the company.

"We are privileged to have identified such an experienced biotech executive" remarked Dr. Joachim Rothe, Chairman of Affectis. "Manfred is taking over the leadership of Affectis in exciting times, and the Board is very much looking forward to working closely with him."

Dr. Rüdiger has extensive experience in the international biotech industry, where he served in various executive positions. He was previously CSO and acting CEO of Cardion AG (Düsseldorf, Germany), CEO of Igeneon AG (Vienna, Austria), COO of NASDAQ-listed Aphton Corporation (Philadelphia, US) and lastly CEO of t2cure GmbH (Frankfurt, Germany). He is currently also Venture Partner in the Munich Office of LSP, and is a member of the Board of Directors of 4SC AG. He has also served on the Boards of Vectron Therapeutics, and G2M AG and Aphton.

"It's a great time to be joining Affectis, with the company's lead compound AFC-5128 generating exciting data and moving toward IND filing" Dr. Rüdiger commented after his appointment. "I look forward to working with the Affectis team to advance the development of its drug candidates into the clinics and to enter partnering agreements with pharma."

About Affectis Pharmaceuticals AG

Affectis is a biopharmaceutical company developing novel drugs for the treatment of psychiatric and neuroinflammatory disorders. Affectis' unique capabilities in drug discovery and behavioral pharmacology allow the company to develop drugs with innovative mechanisms of action based on pioneering findings in depression and neuroinflammation. Affectis was founded in 2004 as a spin-out from the Max Planck Institute of Psychiatry. The Company has the capabilities to move its proprietary drug candidates from discovery to early clinical stage and has successfully advanced several compounds in its development pipeline. At the same time, Affectis is



seeking partnerships with pharmaceutical companies to accelerate development and commercialization of its candidates.

Contact Affectis Pharmaceuticals AG

Luc St-Onge, Ph.D.

Fraunhoferstr. 13

82152 Martinsried, Germany

Tel: +49 (0)89 - 893 2811 100

info@affectis.com